Asunto(s)
Medicina Basada en la Evidencia , Hipersensibilidad al Cacahuete/prevención & control , Guías de Práctica Clínica como Asunto , Especificidad de Anticuerpos , Niño , Preescolar , Consenso , Dietética , Humanos , Inmunoglobulina E/análisis , Lactante , National Institute of Allergy and Infectious Diseases (U.S.) , Ciencias de la Nutrición , Hipersensibilidad al Cacahuete/sangre , Hipersensibilidad al Cacahuete/diagnóstico , Hipersensibilidad al Cacahuete/terapia , Pruebas de Irritación de la Piel , Sociedades Científicas , Estados UnidosRESUMEN
BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy.
Asunto(s)
Arachis/inmunología , Fenómenos Fisiológicos Nutricionales Infantiles , Hipersensibilidad al Cacahuete/prevención & control , Guías de Práctica Clínica como Asunto , Prevención Primaria/normas , Alergia e Inmunología , Niño , Humanos , Tolerancia Inmunológica , National Institute of Allergy and Infectious Diseases (U.S.) , Medición de Riesgo/normas , Conducta de Reducción del Riesgo , Pruebas Cutáneas , Estados UnidosRESUMEN
BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides three separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy.
Asunto(s)
Arachis/inmunología , Hipersensibilidad al Cacahuete/prevención & control , Niño , Humanos , Lactante , National Institute of Allergy and Infectious Diseases (U.S.) , Factores de Riesgo , Pruebas Cutáneas , Estados UnidosRESUMEN
BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy.
Asunto(s)
Hipersensibilidad al Cacahuete/prevención & control , Femenino , Humanos , National Institute of Allergy and Infectious Diseases (U.S.) , Hipersensibilidad al Cacahuete/diagnóstico , Hipersensibilidad al Cacahuete/terapia , Estados UnidosRESUMEN
BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy.
Asunto(s)
Hipersensibilidad al Cacahuete/prevención & control , Alérgenos/inmunología , Arachis/inmunología , Eccema/diagnóstico , Hipersensibilidad al Huevo/diagnóstico , Humanos , Inmunoglobulina E/sangre , Lactante , National Institute of Allergy and Infectious Diseases (U.S.) , Hipersensibilidad al Cacahuete/sangre , Hipersensibilidad al Cacahuete/diagnóstico , Pruebas Cutáneas , Estados UnidosRESUMEN
Immune tolerance-inducing therapies reprogramme immune cells to eliminate pathogenic immune responses while preserving protective immunity. The Immune Tolerance Network (ITN), sponsored by the US National Institutes of Health, was established in 1999 to evaluate new tolerance-inducing therapies and carry out mechanistic studies using a unique interactive approach in partnership with industry, academia and foundations. Ten years later, the ITN has carried out approximately 36 clinical trials and tolerance studies examining innovative tolerogenic approaches in the settings of allergy, autoimmune diseases and organ transplantation. ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN.
Asunto(s)
Ensayos Clínicos como Asunto , Programas de Gobierno , Enfermedades del Sistema Inmune/terapia , Tolerancia Inmunológica/inmunología , Animales , Programas de Gobierno/organización & administración , Humanos , National Institutes of Health (U.S.) , Estados UnidosRESUMEN
The U.S. National Institutes of Health Roadmap and the U.S. Food and Drug Administration's Critical Path Initiative have endorsed the establishment of large academic clinical research networks as part of the solution to the growing divide between increased R&D spending and the lagging number of new drugs making it to market. Clearly, the role of these networks as translational science incubators that complement industry-sponsored programs is laudable and much-needed. However, the path to success for such organizations is less clear. Here, drawing on the experiences of the Immune Tolerance Network, a multidisciplinary clinical research network founded in 1999, we discuss some of the barriers inherent in developing such consortia and offer firsthand insight into the planning, resources, and organizational infrastructure required for a successful research program.
Asunto(s)
Investigación Biomédica , Conducta Cooperativa , Tolerancia Inmunológica , National Institutes of Health (U.S.) , Desarrollo de Programa , Centros Médicos Académicos/economía , Centros Médicos Académicos/organización & administración , Investigación Biomédica/economía , Investigación Biomédica/organización & administración , Financiación Gubernamental/economía , Financiación Gubernamental/organización & administración , Humanos , National Institutes of Health (U.S.)/economía , National Institutes of Health (U.S.)/organización & administración , Desarrollo de Programa/economía , Apoyo a la Investigación como Asunto/economía , Apoyo a la Investigación como Asunto/organización & administración , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Since 1991, the National Institute of Allergy and Infectious Diseases (NIAID) has funded four consecutive research initiatives to investigate the problem of high asthma prevalence, morbidity and mortality in poor urban communities. The multi-site studies conducted under these initiatives have identified key risk factors for asthma morbidity and novel interventions to improve asthma control. NIAID focuses its asthma and allergy programs on understanding the interaction of the immune system with allergens and infectious agents and identifying genetic and epigenetic elements that influence the immune system. A key goal in this field is to define mechanisms of immune system deviation and immune tolerance and apply this knowledge to generate improvements in asthma care and allergen immunotherapy. A related goal is to further understand the environmental, social, and immunological elements that impact on the development of inner-city asthma through in-depth characterization and longitudinal follow-up of inner-city children from the time of birth. In the past 5 years, NIH budgetary constraints have imposed many challenges for the academic research community. Despite these constraints, NIAID has maintained its support of a highly productive asthma and allergy research program.
Asunto(s)
Asma/epidemiología , Asma/etiología , Antiasmáticos/uso terapéutico , Asma/terapia , Servicios de Salud Comunitaria/economía , Servicios de Salud Comunitaria/organización & administración , Humanos , Hipersensibilidad/etiología , National Institute of Allergy and Infectious Diseases (U.S.) , Factores Socioeconómicos , Estados Unidos , Salud Urbana , Población UrbanaAsunto(s)
Asma , National Institutes of Health (U.S.)/historia , National Institutes of Health (U.S.)/organización & administración , Personal Administrativo , Adulto , Asma/epidemiología , Asma/prevención & control , Investigación Biomédica , Niño , Predicción , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Estados UnidosRESUMEN
There have been enormous advances in the field of immunology over the past 3 decades, and those advances have had a positive effect on many subspecialties of medicine. Opportunities for even more notable advances remain. However, present and projected budget constraints for the National Institutes of Health have created formidable challenges. This commentary addresses the opportunities and challenges for the field of immunology during a period of restricted budgets.
Asunto(s)
Alergia e Inmunología/economía , Investigación Biomédica/economía , Presupuestos , Alergia e Inmunología/tendencias , Investigación Biomédica/tendencias , Humanos , National Institutes of Health (U.S.) , Factores de Tiempo , Estados UnidosAsunto(s)
Desensibilización Inmunológica , Tolerancia Inmunológica/efectos de los fármacos , Tolerancia Inmunológica/inmunología , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/inmunología , Especificidad de Anticuerpos/efectos de los fármacos , Especificidad de Anticuerpos/inmunología , Ensayos Clínicos como Asunto , Citocinas/efectos de los fármacos , Citocinas/inmunología , Epítopos/efectos de los fármacos , Epítopos/inmunología , Humanos , Inmunoglobulina E/efectos de los fármacos , Inmunoglobulina E/inmunología , Inmunoglobulina G/efectos de los fármacos , Inmunoglobulina G/inmunologíaRESUMEN
Immune tolerance therapies are designed to reprogram immune cells in a highly specific fashion to eliminate pathogenic responses while preserving protective immunity. A concept that has tantalized immunologists for decades, the development of tolerance-inducing therapies, would revolutionize the management of a wide range of chronic and often debilitating diseases by obviating the need for lifelong immunosuppressive regimens. The advances of the past decade have provided a more detailed understanding of the molecular events associated with T-cell recognition and activation. Building on these advances, immunologists have demonstrated the feasibility of various tolerance-inducing approaches in small- and large-animal models of autoimmunity, allergy, and transplant graft rejection. Unprecedented opportunities to test these approaches in a variety of human diseases have now emerged. To capitalize on these advances, the National Institutes of Health recently established the Immune Tolerance Network (ITN), an international consortium of more than 70 basic and clinical immunologists dedicated to the evaluation of novel tolerance-inducing therapies and associated studies of immunologic mechanisms. By using a unique interactive approach to accelerate the development of clinical tolerance therapies, the ITN is partnering with the biotechnology and pharmaceutical industries to examine innovative tolerogenic approaches in a range of allergic and autoimmune diseases and to prevent graft rejection after transplantation. Two years since its inception, the ITN now has approximately 2 dozen clinical trials or tolerance assays studies ongoing or in later stages of protocol development. This report summarizes the rationale for emphasizing clinical research on immune tolerance and highlights the progress of the ITN.